Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Gilead Sciences (NASDAQ:GILD)

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday released topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy (sacituzumab govitecan-hziy) plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab). The trial demonstrated that Trodelvy plus Keytruda significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative…

Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer

The therapy, used in combination with Keytruda, could provide a new option for women with newly diagnosed, metastatic, triple-negative breast cancer.

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s Keytruda combo.The post Gilead reports topline data from Phase III trial of Trodelvy combo therapy appeared first on Clinical Trials Arena.

Groundbreaking Study Shows Trodelvy and Keytruda Boost Survival in Metastatic Triple-Negative Breast Cancer

In a pivotal Phase III study, Gilead Sciences revealed that combining Trodelvy (sacituzumab govitecan-hziy) with Keytruda (pembrolizumab) significantly enhances progression-free survival (PFS) for patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC). This combination outperformed the standard regimen of Keytruda plus chemotherapy, offering hope for those with this challenging cancer type. Dietmar Berger, MD, PhD, emphasi…

For years, researchers have been trying to curb certain persistent cancers by attacking a key enzyme: CDK7. This small protein plays a central role in cell proliferation, and its dysfunction is linked to several cancers, including triple negative breast cancer, one of the most difficult to treat. Experimental drugs had already been used in [...] More